TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6173896

Group type: EXPERIMENTAL
Intervention: Procedure with sensory and coping behavior information
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sensory information
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Perceived control
Number of subjects: 50
Study: 31558414

Group type: EXPERIMENTAL
Intervention: Genetically-predicted 50% increase of coffee consumption
Number of subjects: 588190

Group type: EXPERIMENTAL
Intervention: Weighted median and MR-Egger methods
Number of subjects: 588190

Group type: EXPERIMENTAL
Intervention: Coffee-related single-nucleotide polymorphisms based on association with blood levels of caffeine metabolites
Number of subjects: 588190
Study: 28856093

Group type: EXPERIMENTAL
Intervention: ASD‐EXP (reading intervention program: 4-hour sessions per day, 5 days a week for 10 weeks)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: ASD‐EXP (reading intervention program)
Number of subjects: 25

Group type: COMPARATOR
Intervention: ASD‐WLC (waitlist control group)
Number of subjects: 25
Study: 26530648

Group type: EXPERIMENTAL
Intervention: Cemented Exeter stem
Number of subjects: 141

Group type: COMPARATOR
Intervention: Uncemented Bimetric stem
Number of subjects: 141
Study: 23557603

Group type: EXPERIMENTAL
Intervention: Higher propensity for sexual arousability
Number of subjects: 701

Group type: COMPARATOR
Intervention: Lower propensity for sexual arousability
Number of subjects: 701
Study: 22067309

Group type: EXPERIMENTAL
Intervention: Donor Desmopressin (DDAVP)
Number of subjects: 487

Group type: COMPARATOR
Intervention: Control (nondopamine group)
Number of subjects: 487
Study: 19142258

Group type: EXPERIMENTAL
Intervention: Potassium nitrate
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Gluma Desensitizer
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (no substance)
Number of subjects: 75
Study: 17533389

Group type: EXPERIMENTAL
Intervention: Adjuvant imatinib treatment
Number of subjects: 23

Group type: COMPARATOR
Intervention: Surgery alone (Control)
Number of subjects: 23
Study: 17198591

Group type: EXPERIMENTAL
Intervention: Backward walking treadmill training (30-minute conventional training + 30-minute backward walking training, five times a week for three weeks)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional training (60 minutes, five times a week for three weeks)
Number of subjects: 26
Study: 14659523

Group type: EXPERIMENTAL
Intervention: Real acupuncture for 2 weeks
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo acupuncture (Streitberger needle) for 2 weeks
Number of subjects: 37
Study: 10390201

Group type: EXPERIMENTAL
Intervention: Aminoglycosides administered twice daily
Number of subjects: 123

Group type: COMPARATOR
Intervention: Aminoglycosides administered once daily
Number of subjects: 123
Study: 8894194

Group type: EXPERIMENTAL
Intervention: mianserin
Number of subjects: 55

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 55
Study: 1672278

Group type: EXPERIMENTAL
Intervention: Prophylactic somatostatin infusion before, during, and after the procedure
Number of subjects: 16
Study: 6711925

Group type: EXPERIMENTAL
Intervention: Halothane 0.5%
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Enflurane 1.5%
Number of subjects: 30
Study: 31483162

Group type: EXPERIMENTAL
Intervention: not willing/non-consent
Number of subjects: 615

Group type: COMPARATOR
Intervention: refusal
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: not willing/non-consent and refusal
Number of subjects: 615
Study: 30845084

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite granules and bone marrow aspirate in collagen sponge
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hydroxyapatite granules only
Number of subjects: 30
Study: 27748055

Group type: EXPERIMENTAL
Intervention: Fulranumab (1 mg every 4 weeks)
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Fulranumab (3 mg every 4 weeks)
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Fulranumab (10 mg every 8 weeks)
Number of subjects: 423

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Fulranumab (all doses)
Number of subjects: 423
Study: 25798990

Group type: COMPARATOR
Intervention: Chef-enhanced meals
Number of subjects: 2638

Group type: COMPARATOR
Intervention: Smart café intervention
Number of subjects: 2638

Group type: COMPARATOR
Intervention: Chef plus smart café
Number of subjects: 2638

Group type: EXPERIMENTAL
Intervention: Control group
Number of subjects: 2638
Study: 23688527

Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 936

Group type: COMPARATOR
Intervention: PPSV23
Number of subjects: 936

Group type: EXPERIMENTAL
Intervention: PCV13 (follow-on dose after 1 year)
Number of subjects: 936
Study: 21715512

Group type: EXPERIMENTAL
Intervention: Iron-containing micronutrient powder (iron MNP)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Placebo powder (PP)
Number of subjects: 268
Study: 19458427

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) of the gluteus medius muscles during walking
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: NMES program with 15 minutes of simultaneous and continuous NMES of both gluteus medius muscles during walking, three sessions a day for a week
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: NMES program designed to detect additional changes in gait after adaptation to NMES
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group of ten ambulant spastic diplegic children with CP
Number of subjects: 21

Group type: COMPARATOR
Intervention: Healthy control group with twenty normal children
Number of subjects: 21
Study: 16675326

Group type: EXPERIMENTAL
Intervention: Ciclesonide 40 microg/80 microg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Ciclesonide 160 microg/320 microg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Ciclesonide 320 microg
Number of subjects: 26
Study: 15701185

Group type: EXPERIMENTAL
Intervention: Laparoscopic excision of endometriomas with the stripping technique followed by serial transvaginal ultrasound examinations.
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Follow-up ultrasound at the third menstrual cycle after surgery.
Number of subjects: 47
Study: 11503007

Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg twice daily (1 day before treatment and 3 days of concomitant administration)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Rifampin 300 mg twice daily (3 days before treatment and 3 days of concomitant administration)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Ifosfamide alone
Number of subjects: 16
Study: 9266289

Group type: EXPERIMENTAL
Intervention: Spironolacton 50 Heumann
Number of subjects: 24

Group type: COMPARATOR
Intervention: Aldactone 50
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Canrenone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 7 alpha-thiomethylspirolactone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Spironolactone and Canrenone
Number of subjects: 24
Study: 8007702

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (cyclophosphamide, methotrexate and 5-fluorouracil - CMF)
Number of subjects: 3427

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 3427
Study: 3527011

Group type: EXPERIMENTAL
Intervention: 100 mg of almitrine bismesylate twice daily
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: 50 mg of almitrine bismesylate twice daily
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 31738382

Group type: EXPERIMENTAL
Intervention: Noninvasive testing with coronary computed tomographic angiography
Number of subjects: 8966

Group type: EXPERIMENTAL
Intervention: Functional testing
Number of subjects: 8966

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 8966
Study: 30301127

Group type: EXPERIMENTAL
Intervention: Flavanol-rich cocoa (2.5 g/day for 12 weeks)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Cocoa-free capsules (placebo)
Number of subjects: 42
Study: 28988541

Group type: EXPERIMENTAL
Intervention: Artefenomel 800 mg plus PQP 640 mg
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Artefenomel 800 mg plus PQP 960 mg
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Artefenomel 800 mg plus PQP 1440 mg
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Artefenomel 800 mg plus PQP (all doses)
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Artefenomel 800 mg plus PQP (in African population)
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Artefenomel 800 mg plus PQP (in Vietnam)
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Artefenomel 800 mg plus PQP
Number of subjects: 437
Study: 26642329

Group type: EXPERIMENTAL
Intervention: Internet-based brief alcohol primary prevention intervention (IBI)
Number of subjects: 896

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 896
Study: 23203216

Group type: EXPERIMENTAL
Intervention: HYAL group (hyaluronan-bound sperm)
Number of subjects: 802

Group type: COMPARATOR
Intervention: Control group (conventional assessment of motility and morphology)
Number of subjects: 802
Study: 21296803

Group type: EXPERIMENTAL
Intervention: Cessation of progesterone supplementation on the 16th day post-ET (study group, n = 100)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Continuation of progesterone supplementation until 7 weeks of gestation (control group, n = 100)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Cessation of progesterone supplementation (study group)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Continuation of progesterone supplementation (control group)
Number of subjects: 200
Study: 18465335

Group type: EXPERIMENTAL
Intervention: Breast conserving surgery (BCS)
Number of subjects: 1154

Group type: COMPARATOR
Intervention: Mastectomy (M)
Number of subjects: 1154
Study: 16531905

Group type: EXPERIMENTAL
Intervention: CLA (5 g.d(‐1))
Number of subjects: 76
Study: 12975188

Group type: EXPERIMENTAL
Intervention: Early weightbearing with ankle in plantigrade position
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard immobilization with ankle in full equinus
Number of subjects: 0
Study: 12534358

Group type: EXPERIMENTAL
Intervention: 250 microg (5000 IU) r‐hCG subcutaneously twice each week for 3 months (n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo injections for 3 months (n=20)
Number of subjects: 40
Study: 10390407

Group type: EXPERIMENTAL
Intervention: Formoterol (120 micrograms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salmeterol (250 micrograms)
Number of subjects: 0
Study: 9484091

Group type: EXPERIMENTAL
Intervention: Pulsed Nd:YAG laser treatment (Group A) with varying power levels (0.8 W, 1.0 W, 1.2 W, 1.5 W)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Conventional scaling alone (Group B)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser treatment at different power levels
Number of subjects: 14
Study: 1862585

Group type: EXPERIMENTAL
Intervention: HIV‐Chek (Du Pont)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: HIV‐1/HIV‐2 TestPack (Abbott)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Recombigen (BioScience)
Number of subjects: 30
Study: 6348378

Group type: EXPERIMENTAL
Intervention: Standard dose of methylprednisolone (MP)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Low-dose regimen of methylprednisolone (MP)
Number of subjects: 86
Study: 31575537

Group type: EXPERIMENTAL
Intervention: Integrated GP care for persistent physical symptoms; details on dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (waiting list); details on dosage and duration not available.
Number of subjects: 0
Study: 30005705

Group type: EXPERIMENTAL
Intervention: Complex multiple risk behaviour intervention
Number of subjects: 26

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 26
Study: 27406589

Group type: EXPERIMENTAL
Intervention: Low dose bevacizumab (5 mg/kg) plus lomustine (90 mg/m²)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Standard dose bevacizumab (10 mg/kg)
Number of subjects: 71
Study: 24820191

Group type: EXPERIMENTAL
Intervention: Society of Thoracic Surgeons (STS) score
Number of subjects: 2466

Group type: EXPERIMENTAL
Intervention: logistic European System for Cardiac Operative Risk Evaluation (LES) score
Number of subjects: 2466
Study: 22895694

Group type: EXPERIMENTAL
Intervention: Hemiarthroplasty
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 50
Study: 20592630

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (two cycles of cisplatin and vinorelbine followed by radiotherapy together with third cycle)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Radiotherapy alone (30 Gy/10 fractions)
Number of subjects: 99
Study: 19845074

Group type: EXPERIMENTAL
Intervention: Verapamil sustained release (SR) + Trandolapril (Ve + Tr)
Number of subjects: 1170

Group type: COMPARATOR
Intervention: Atenolol + Hydrochlorothiazide (At + HCTZ)
Number of subjects: 1170
Study: 15957690

Group type: EXPERIMENTAL
Intervention: Intrathecal neostigmine
Number of subjects: 19
Study: 11852292

Group type: EXPERIMENTAL
Intervention: Citalopram (10 mg/d for 1 week, then 20 mg/d) in depressed patients (n = 18) and half of the nondepressed subgroup (n = 14)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Citalopram (10 mg/d for 1 week, then 20 mg/d)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Citalopram combined with levodopa
Number of subjects: 46
Study: 9787148

Group type: EXPERIMENTAL
Intervention: High-dose therapy (HDT) with autologous stem cell support (early HDT group, n = 91)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Conventional-dose chemotherapy (CCT) regimen (late HDT group, n = 94)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: High-dose therapy (HDT) with autologous stem cell support (early HDT group)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Conventional-dose chemotherapy (CCT) regimen (late HDT group)
Number of subjects: 202
Study: 7674688

Group type: EXPERIMENTAL
Intervention: Calcium channel blockers and beta-blockers for rate control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose anticoagulation therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anticoagulation therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amiodarone in low doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No anticoagulation or antiplatelet therapy
Number of subjects: 0
Study: 2379359

Group type: EXPERIMENTAL
Intervention: Static reconstruction (Group S)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Dynamic reconstruction (Group D)
Number of subjects: 82
Study: 581950

Group type: EXPERIMENTAL
Intervention: 0.5 mg digoxin orally
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0.5 mg digoxin i.v.
Number of subjects: 10
Study: 29455421

Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 544
Study: 27851668

Group type: EXPERIMENTAL
Intervention: RTI (Resistance Training with Instability)
Number of subjects: 39

Group type: COMPARATOR
Intervention: RT (Resistance Training)
Number of subjects: 39
Study: 26666738

Group type: EXPERIMENTAL
Intervention: Intraoperative infusion of branched-chain amino acids (BCAA) solution (N = 20)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Intraoperative infusion of amino acids (AA) solution (N = 21)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Normal saline (NS) (N = 20)
Number of subjects: 61
Study: 24459689

Group type: EXPERIMENTAL
Intervention: SHED‐IT weight loss program
Number of subjects: 145
Study: 21324747

Group type: EXPERIMENTAL
Intervention: Intracytoplasmic morphologically selected sperm injection (IMSI)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Conventional intracytoplasmic sperm injection (ICSI)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Intracytoplasmic morphologically selected sperm injection (IMSI) in severe male factor patients
Number of subjects: 168

Group type: COMPARATOR
Intervention: Conventional intracytoplasmic sperm injection (ICSI) in severe male factor patients
Number of subjects: 168
Study: 18292452

Group type: COMPARATOR
Intervention: Preoperative PVB with 20 mL of ropivacaine 0.5%
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Continuous ropivacaine 0.5% infusion (CRI) at a 2 mL/h rate for 24 h
Number of subjects: 48
Study: 16502745

Group type: EXPERIMENTAL
Intervention: Cyriax physiotherapy
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Supervised exercise programme
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Polarized polychromatic non‐coherent light (Bioptron light)
Number of subjects: 75
Study: 14637276

Group type: EXPERIMENTAL
Intervention: Conventional treatment supplemented with antioxidants for 12 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional treatment for 12 weeks
Number of subjects: 40
Study: 11712326

Group type: COMPARATOR
Intervention: EGG recording during fasting state
Number of subjects: 10

Group type: COMPARATOR
Intervention: EGG recording after a standard meal
Number of subjects: 10

Group type: COMPARATOR
Intervention: 24-hours pH-metry
Number of subjects: 10

Group type: COMPARATOR
Intervention: De Meester and Johnson scoring
Number of subjects: 10

Group type: COMPARATOR
Intervention: Correlation analysis
Number of subjects: 10
Study: 9223116

Group type: EXPERIMENTAL
Intervention: T lymphocytes stimulated by anti-CD3 mAb
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: T lymphocytes stimulated by phorbol myristate acetate (PMA)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: T lymphocytes stimulated by anti-CD3 mAb and costimulated by CD28 mAb
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: T lymphocytes stimulated by PMA and costimulated by CD28 mAb
Number of subjects: 40
Study: 7956400

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with etoposide (100 mg/m2), cisplatin (25 mg/m2), ifosfamide (1.5 g/m2), and mesna (1.8 g/m2) for 4 days, 3 cycles every 21 days
Number of subjects: 33
Study: 3314173

Group type: EXPERIMENTAL
Intervention: Cimetidine retard
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-retard cimetidine preparation
Number of subjects: 0
Study: 2179096

Group type: EXPERIMENTAL
Intervention: Oral propranolol (dosage to reduce resting pulse rate by 25%)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Long-term injection sclerotherapy
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Both groups (propranolol and sclerotherapy)
Number of subjects: 108
Study: 1097148

Group type: EXPERIMENTAL
Intervention: THC 20 mg + CBN 40 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: THC 20 mg + CBD 40 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: THC 20 mg + Placebo
Number of subjects: 0
Study: 30601349

Group type: EXPERIMENTAL
Intervention: Buzzy device
Number of subjects: 200

Group type: COMPARATOR
Intervention: Handheld computer
Number of subjects: 200
Study: 31866256

Group type: EXPERIMENTAL
Intervention: In-class delivery of feeding content and nutrition education
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Online delivery of feeding content and in‐class delivery of nutrition education
Number of subjects: 540

Group type: COMPARATOR
Intervention: Nutrition education only
Number of subjects: 540
Study: 30767409

Group type: EXPERIMENTAL
Intervention: 125 g of frozen red raspberries (RR-125)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 250 g of frozen red raspberries (RR-250)
Number of subjects: 32

Group type: COMPARATOR
Intervention: 0 g of frozen red raspberries (Control)
Number of subjects: 32
Study: 28376877

Group type: EXPERIMENTAL
Intervention: Inhaled loxapine
Number of subjects: 360

Group type: COMPARATOR
Intervention: Intramuscular aripiprazole
Number of subjects: 360
Study: 25832312

Group type: EXPERIMENTAL
Intervention: CZP 200 mg every 2 weeks
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: CZP 400 mg every 4 weeks
Number of subjects: 325

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: CZP 200 mg every 2 weeks and CZP 400 mg every 4 weeks
Number of subjects: 325
Study: 23731852

Group type: EXPERIMENTAL
Intervention: Quadrupedal head position
Number of subjects: 106

Group type: COMPARATOR
Intervention: Non-quadrupedal head position
Number of subjects: 106
Study: 21832988

Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg) + Active cognitive bias training
Number of subjects: 62

Group type: COMPARATOR
Intervention: Citalopram (20 mg) + Control cognitive bias training
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo + Active cognitive bias training
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo + Control cognitive bias training
Number of subjects: 62
Study: 19627023

Group type: EXPERIMENTAL
Intervention: Lidocaine 20 mg
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Granisetron 2 mg
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Granisetron 2 mg plus Lidocaine
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Granisetron/lidocaine combination
Number of subjects: 200
Study: 17658696

Group type: EXPERIMENTAL
Intervention: Brief Motivational Intervention (BMI)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Alcohol Expectancy Challenge (AEC)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: BMI and AEC (combined)
Number of subjects: 335

Group type: COMPARATOR
Intervention: Assessment only (control)
Number of subjects: 335
Study: 14511967

Group type: EXPERIMENTAL
Intervention: Intervention group (booklet about postnatal depression, prenatal screening, discussion, alert letter)
Number of subjects: 509

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 509
Study: 10444050

Group type: EXPERIMENTAL
Intervention: Hydrogel contact lenses with varying water content
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: FDA Group IV lenses
Number of subjects: 2
Study: 8542123

Group type: EXPERIMENTAL
Intervention: CT scan evaluation
Number of subjects: 133

Group type: COMPARATOR
Intervention: Fiberoptic bronchoscopy (FOB)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Cox's hazard model
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: CT scan
Number of subjects: 133
Study: 1676524

Group type: EXPERIMENTAL
Intervention: 100 mg remoxipride
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 200 mg sulpiride
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12